Marker that predicts cell death in kidneys identified

When the kidneys are damaged—after surgery, cardiac arrest, or as a side effect of certain medications—doctors often face one ...
Targeted Oncology

Perioperative Disitamab Vedotin/Tislelizumab Shows Promise in High-Risk UTUC

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
Le Lézard

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary ...

Vertex Pharmaceuticals Incorporated today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the ...

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Third quarter performance driven by strong portfolio royalty revenue growth of 47%2025 full year revenue guidance increased to $225 million - ...
EurekAlert!

Researchers identify marker that predicts cell death in kidneys

Researchers from Aarhus University have discovered a protein that can predict whether kidney cells will survive or die after acute injury. The finding could pave the way for new treatments and benefit ...